Atara Biotherapeutics Stock Forecast, Price & News

Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

Is Atara Biotherapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Atara Biotherapeutics stock.
View analyst ratings for Atara Biotherapeutics or view top-rated stocks.

How has Atara Biotherapeutics' stock price been impacted by Coronavirus (COVID-19)?

Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATRA shares have increased by 76.4% and is now trading at $17.57.
View which stocks have been most impacted by COVID-19.

When is Atara Biotherapeutics' next earnings date?

Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Atara Biotherapeutics.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.02. During the same quarter in the previous year, the business earned ($0.92) earnings per share.
View Atara Biotherapeutics' earnings history.

What price target have analysts set for ATRA?

7 equities research analysts have issued 1-year price objectives for Atara Biotherapeutics' stock. Their forecasts range from $27.00 to $41.00. On average, they expect Atara Biotherapeutics' stock price to reach $30.33 in the next twelve months. This suggests a possible upside of 72.6% from the stock's current price.
View analysts' price targets for Atara Biotherapeutics or view top-rated stocks among Wall Street analysts.

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the following people:

• Pascal Touchon, President, Chief Executive Officer & Director (LinkedIn Profile)
• Joseph Newell, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
• Utpal Koppikar, Chief Financial Officer & Senior Vice President (LinkedIn Profile)
• Manher AJ Joshi, Chief Medical Officer
• Jakob Dupont, Global Head-Research & Development (LinkedIn Profile)

What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

6 employees have rated Atara Biotherapeutics CEO Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among Atara Biotherapeutics' employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Atara Biotherapeutics' key competitors?

Some companies that are related to Atara Biotherapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Exelixis (EXEL), Beam Therapeutics (BEAM), Abcam (ABCM), Fate Therapeutics (FATE), Kodiak Sciences (KOD), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Sana Biotechnology (SANA), SpringWorks Therapeutics (SWTX) and Relay Therapeutics (RLAY).
View all of ATRA's competitors.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Maverick Capital Ltd. (8.88%), BlackRock Inc. (8.65%), Wasatch Advisors Inc. (3.29%), Goldman Sachs Group Inc. (3.39%), Morgan Stanley (3.18%) and Point72 Asset Management L.P. (2.62%). Company insiders that own Atara Biotherapeutics stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends for Atara Biotherapeutics.

Which institutional investors are selling Atara Biotherapeutics stock?

ATRA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, Bridger Management LLC, Credit Suisse AG, Alberta Investment Management Corp, Millennium Management LLC, Two Sigma Investments LP, and Morgan Stanley. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Amar Murugan, Jakob Dupont, Joe Newell, Matthew K Fust, Pascal Touchon, Thomas Peterffy, and Utpal Koppikar.
View insider buying and selling activity for Atara Biotherapeutics or view top insider-selling stocks.

Which institutional investors are buying Atara Biotherapeutics stock?

ATRA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., 683 Capital Management LLC, Wasatch Advisors Inc., Lion Point Capital LP, Goldman Sachs Group Inc., Integral Health Asset Management LLC, Maverick Capital Ltd., and Natixis.
View insider buying and selling activity for Atara Biotherapeutics or or view top insider-buying stocks.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $17.57.

How much money does Atara Biotherapeutics make?

Atara Biotherapeutics has a market capitalization of $1.55 billion. The biotechnology company earns $-306.62 million in net income (profit) each year or ($3.62) on an earnings per share basis.

How many employees does Atara Biotherapeutics have?

Atara Biotherapeutics employs 437 workers across the globe.

What is Atara Biotherapeutics' official website?

The official website for Atara Biotherapeutics is www.atarabio.com.

Where are Atara Biotherapeutics' headquarters?

Atara Biotherapeutics is headquartered at 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 278-8930 or via email at [email protected].